Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KJ017 recombinant human hyaluronidase to facilitate subcutaneous infusion in healthy volunteers
CTR20241071Phase 3Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Apr 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of KJ017 in None (2 arms), sponsored by Suzhou Ribo Life Science Co., Ltd. Primary endpoint: Rate of subcutaneous infusion. Started Apr 2024; status: completed.
02
Drugs
KJ017
Beyond the preview
Go deeper on CTR20241071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241071.